To the full analysis
Buyback calculator for Sino Biopharmaceutical
Sino Biopharmaceutical stock: key metrics
1177.HKSino Biopharmaceutical had an operating margin of 21.8% and a return on invested capital (ROIC) of 14.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 81.1% | 32.4% | 19.2% |
| 2007 | 79.2% | 21.2% | 18.5% |
| 2008 | 79.3% | 26.7% | 13.0% |
| 2009 | 80.3% | 24.7% | 12.2% |
| 2010 | 80.8% | 26.8% | 13.9% |
| 2011 | 78.5% | 17.4% | 8.0% |
| 2012 | 78.5% | 24.0% | 11.9% |
| 2013 | 77.5% | 17.5% | 10.5% |
| 2014 | 76.4% | 20.3% | 12.2% |
| 2015 | 77.7% | 22.0% | 12.2% |
| 2016 | 79.2% | 21.1% | 12.1% |
| 2017 | 79.1% | 21.8% | 14.6% |
| 2018 | 79.9% | 20.7% | 43.3% |
| 2019 | 79.7% | 21.4% | 11.4% |
| 2020 | 78.1% | 17.7% | 11.7% |
| 2021 | 80.1% | 19.2% | 54.4% |
| 2022 | 82.8% | 21.5% | no data |
| 2023 | 81.0% | 21.6% | no data |
| 2024 | 81.5% | 21.3% | no data |
| 2025 | 82.1% | 21.8% | 7.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 7.4% | 61.1% | 6.4% |
| 2007 | 11.1% | 52.9% | 8.6% |
| 2008 | 13.4% | 69.2% | 9.1% |
| 2009 | 16.0% | 65.7% | 10.5% |
| 2010 | 15.5% | 61.5% | 10.1% |
| 2011 | 12.1% | 38.9% | 7.4% |
| 2012 | 19.4% | 51.3% | 11.4% |
| 2013 | 18.9% | 38.8% | 10.4% |
| 2014 | 22.9% | 43.9% | 10.7% |
| 2015 | 22.9% | 45.5% | 10.8% |
| 2016 | 20.6% | 45.7% | 8.9% |
| 2017 | 23.6% | 51.9% | 10.4% |
| 2018 | 31.0% | 24.1% | 18.2% |
| 2019 | 8.9% | 15.2% | 4.7% |
| 2020 | 16.5% | 14.5% | 5.9% |
| 2021 | 48.2% | 17.0% | 24.1% |
| 2022 | no data | 14.0% | no data |
| 2023 | no data | 13.5% | no data |
| 2024 | no data | 14.9% | no data |
| 2025 | 7.6% | 14.5% | 3.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 16 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.